Rapid and sensitive oligonucleotide ligation assay for detection of mutations in human immunodeficiency virus type 1 associated with high-level resistance to protease inhibitors

Journal of Clinical Microbiology

Volumn 40, Issue 4, 2002, Pages 1413-1419

  Beck, Ingrid A ^a   Mahalanabis, Madhumita ^a   Pepper, Gregory ^a   Wright, Amy ^a   Hamilton, Shannon ^a   Langston, Erika ^a   Frenkel, Lisa M ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; INDINAVIR; LOPINAVIR; NELFINAVIR; OLIGONUCLEOTIDE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

AMINO ACID SUBSTITUTION; AMPLICON; ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; DNA SEQUENCE; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; MICROTITER PLATE ASSAY; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; VIRUS MUTATION;

BASE SEQUENCE; DNA LIGASES; DRUG RESISTANCE, VIRAL; GENE PRODUCTS, POL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDES; POINT MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; TIME FACTORS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0036208482     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.40.4.1413-1419.2002     Document Type: Article

References (33)

1. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: Outcome after treatment in recently infected individuals
2. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy
3. Rapid and simple method for purification of nucleic acids
4. Polymorphism of the human immunodeficiency virus type 1 (HIV-1) protease gene and response of HIV-1-infected patients to a protease inhibitor
5. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor
6. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
7. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomized controlled trial
8. Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy
9. Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine
10. - cell surviving infection with the acquired immune deficiency syndrome retrovirus
11. International perspectives on antiretroviral resistance. Clinical utility of resistance testing: Retrospective and prospective data supporting use and current recommendations
12. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: Mutations, kinetics, and frequencies
13. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients
14. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleoticle arrays
15. A ligase-mediated gene detection technique
16. Transmission and prevalence of HIV resistance among treatment-naive subjects
17. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor
18. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection
19. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
20. AmpliTaq® DNA polymerase, FS dye-terminator sequencing: Analysis of peak height patterns
21. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease
22. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease
23. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase
24. Human immunodeficiency virus reverse transcriptase and protease sequence database
25. Identification of biased amino acid substitution patterns in human immunodeficiency virus type 1 isolates from patients treated with protease inhibitors
26. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene
27. Single-well genotyping of diallelic sequence variations by a two-color ELISA-based oligonucleotide ligation assay
28. Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations
29. Public health implications of antiretroviral therapy and HIV drug resistance
30. Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naive HIV-1 infected US military personnel
31. Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment
32. Transmission of antiretroviral-drug-resistant HIV-1 variants